Advaxis, a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a non-exclusive research and clinical trial collaboration agreement with Sorrento Therapeutics to evaluate combinations of Advaxis’s Lm-LLO cancer immunotherapy technology platform, including ADXS-HPV, ADXS-PSA and ADXS-HER2, with Sorrento’s fully human antibodies targeting immune checkpoints, including GITR, OX40, LAG-3 and TIM-3. Advaxis’s preclinical program for ADXS-HPV previously examined ...